Literature DB >> 11153358

[Botulinum toxin: from poison to drug. A historical review].

O P Kreyden1, M L Geiges, R Böni, G Burg.   

Abstract

Botulinumtoxin (BTX) is a neurotoxin produced from Clostridium botulinum under anaerobic conditions and is responsible for botulism, a notifiable, bacterial form of food poisoning. The first case of botulism is believed to have occurred in 1735. An epidemic in Southern Germany in 1793 claimed the death of over the half of those patients who had become ill through eating uncooked blood sausages. The term "pharmakon" is Greek and implicates that a drug originates from poison (potion, remedy). Theophrastus Bombast von Hohenheim known as Paracelsus (1493/94-1541) first described this duality with his dictum "alle ding sind gift und nichts on gift; alein die dosis macht das ein ding kein gift ist" (only the dose makes a remedy poisonous). In Baden-Württemberg in 1817, the poet and physician Dr. Justinus Christian Kerner described the symptoms of botulism, so that at this time botulism was also called Kerner disease. Until the turn of the century the reason for poisoning was not known. Van Ermengem succeeded in isolating the anaerobic bacterium causing botulism, but the specific mechanism of BTX was only established after the second World War. In the late seventies the ophthalmologist Dr. Alan Scott used BTX the first time in the treatment of strabismus. The drug was then used in the treatment of several muscle spasticities such as, for example, torticollis or hemifacial spasm. Only recently BTX has been successfully used for focal hyperhidrosis. We review the history of botulinum toxin from its discovery in the nineteenth century and the research into its effect in the middle of the 20th century up to its clinical use at the present time.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11153358     DOI: 10.1007/s001050051206

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  6 in total

1.  [Botulinum toxin treatment of eccrine sweat gland nevus].

Authors:  M Sonntag; L Rauch; T Ruzicka; D Bruch-Gerharz
Journal:  Hautarzt       Date:  2005-04       Impact factor: 0.751

2.  [Chemodenervation with botulinumtoxin in masseteric hypertrophy].

Authors:  R A Mischkowski; M Siessegger; F Lazar; J E Zöller
Journal:  Mund Kiefer Gesichtschir       Date:  2005-03

3.  Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study.

Authors:  Hessa Al-Wayli
Journal:  J Clin Exp Dent       Date:  2017-01-01

Review 4.  The Evolving View of Uremic Toxicity.

Authors:  Bjorn Meijers; Jerome Lowenstein
Journal:  Toxins (Basel)       Date:  2022-04-12       Impact factor: 5.075

Review 5.  Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury.

Authors:  Ramiro Palazón-García; Ana María Benavente-Valdepeñas
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

6.  Quo Vadis Botulinum Toxin: Normative Constraints and Quality of Life for Patients With Idiopathic OAB?

Authors:  Sandra Mühlstädt; Shahidul Mischner; Jennifer Kranz; Petra Anheuser; Nasreldin Mohammed; Joachim A Steffens; Paolo Fornara
Journal:  Front Surg       Date:  2018-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.